The cytotoxic activity of the new compounds was assessedusing the MTT dye reduction assay.results And conclusionsTwo new potential anticancer compounds were synthesized and weretested for in vitro cytotoxic activity on a panel of human leukemic andtumor cell lines.references[1] Savini L., Massarelli P., Travagli V., Pellerano C., Novellino E., Cosentino S., et al.New a-(N) heterocyclic hydrazones: evaluation of anti-cancer, anti-HIV and antimi-crobial activity. Eur J Med Chem. 2004;39:113-22[2] Ponka P., Borova J., Neuwirt J., Fuchs O. Mobilization of iron reticulocytes. FEBSLett. 1979;97:317-21[3] Richardson D R., Bernhardt P. V. Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron (III) complex: an iron chela-tor with anti-tumor activity. J Biol Inorg Chem. 1999;4:266-73. [4] Johnson DK, Murphy TB, Rose NJ, Goodwin WH, Pickart L. Cytotoxic chelators andchelates 1. Inhibition of DNA synthesis in cultured rodent and human cells byaroylhydrazones and by a copper (II) complex of salicylaldehyde benzoyl hydrazone.Inorg Chim Acta. 1982; 67:159-65. [5] Pickart L, Goodwin WH, Murphy TB, Johnson DK, J Cell Biochem Suppl.1982;6:L482. [6] Pickart L, Goodwin WH, Burgua W, Murphy TB, Johnson DK. Inhibition of the growthof cultured cells and an implanted fibrosarcoma by aroylhydrazone analogs of theGly-His-Lys-Cu (II) complex. Biochem Pharmacol. 1983;32:3868-71.An unexpected product fromthe reAction of AcenocoumArolAnd phosphoryl chlorideE. Stanojevska1, K. Mladenovska1,A. Poceva Panovska1, B. Mikhova2, E. Popovski31University "Ss Cyril and Methodius", Faculty of Pharmacy,Vodnjanska 17, 1000 Skopje, Macedonia2Institute of Organic Chemistry with Centre of Phytochemistry,Bulgarian Academy of Sciences, Acad. G. Bonchev Str., Build. 9,1113 Sofia, Bulgaria3Institute of Chemistry, Faculty of Natural Sciences and Mathematics,Ss. Cyril and Methodius University, Arhimedova 5, 1000 Skopje,P.O. Box 162, Macedonia.introductionCoumarins are large class of compounds with the common structureof benzo-a-pyrone (2H-1-benzopiran-2-one). The family of coumarins ischaracterized by wide structural diversity. According to the substitu-tion in benzene and pyrone rings they can be generally classified inthe following categories: (i) simple coumarins, (ii) furano-coumarins,(iii), pyranocoumarins, (iv) biscoumarins and triscoumarins, and (v)coumarinolignans.Simple coumarins and their analogues, such as bis and tris-cumarinscontinually attract research interest due to their diverse biologicalactivities, such as anticoagulant, anti-inflammatory, anti-tumoral,antimicrobial and antioxidant activity. Also, they have been reportedto be CNS active and possess enzyme inhibition properties. Theseproperties of coumarins made them very attractive for re-design,organic synthesis and development [1].Acenocoumarol (1) [(RS)-4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one, logP 1,98; logS (predicted) -4,53] is an anticoagulantthat functions as a vitamin K antagonist. Molecule of acenocoumarolhas a single chiral center that gives rise to two different enantiomericforms. (R)-(+)-Acenocoumarol has a longer plasma elimination half-lifeand slower plasma clearance, compared to the (S)-(-)-enantiomer. Re-lated to these pharmacokinetic characteristics, (R)-(+)-acenocoumarolis more potent in vivo as an anti-coagulant than the (S)-(-)-enantiomerand is largely responsible for the overall anticoagulant response [2].Acenocumarol is metabolized predominantly by CYP2C9, while itstarget on the enzyme vitamin K epoxidase is VKORC1. Genetic variantsin CYP2C9 and VKORC1 are associated with variability in coumarinanticoagulant dose requirement, over-anticoagulation, bleeding riskand stabilization [3, 4].Starting from acenocoumarol as a leading compound our aim was tosynthesize a novel 4-amino derivate of acenocoumarol. Due to the elec-tronic similarity of oxygen (hydroxyl group) and nitrogen (amino group)we supposed that (RS)-4-amino-3-[1-(4-nitrophenyl)-3-oxobutyl]-2H-chromen-2-one (3) could be a potential bioisostere of acenocoumarol.mAteriAls And methodssynthesis of(rs)-2-methyl-4-(4-nitrophenyl)pyrano(-) [3,2-c]chromen-5-one (4)The mixture of (RS)-Acenocoumarol (Alkaloida Chemical Co) and POCl3(Merck Chemicals) was heated at 70 oC for 4 hours. Afterwards, the re-action mixture was cooled to room temperature then slowly pouredonto crushed ice and stirred for 45 min. Crystals of 4 were formed,which were separated by filtration and washed with cold water.The obtained compound was characterized by FTIR, 1H-NMR (fig. 1)and 13C-NMR (fig. 2) spectra.Fig. 1. 1H-NMR spectra of 4343fifth congress of phArmAcy of mAcedoniA with internAtionAl pArticipAtionMacedonian Pharmaceutical Bulletin 57 (suppl), 2011PHARMACEUTICAL CHEMISTRY / BIOMOLECULAR SCIENCESposter presentationsresults And discussionFirst, the reaction of 1 with phosphoryl chloride was performed to ob-tain 4-chloro derivative 2a. Subsequently, target compound 3 wasplanned to be obtained in nucleophiic reaction of ammonia with in-termediate 2a (scheme 1). However, after the first step and replace-ment of the hydroxyl group in position 4 at coumarin moiety,unplanned cyclization occurred. With intramolecular nucleophilic at-tack, oxygen from hydroxyl group at enolate form 2b replace chlorineatom resulting in formation of compound 4. The reaction was per-formed at three different temperatures (70 oC, 90 oC and boiling tem-perature of phosphoryl chloride) in order 2a to be obtained andisolated. However, in all the reaction conditions, as a product of reac-tion, the compound 4 was obtained. Thus, the future research will beaimed to synthesize and isolate compound 2a as intermediate for ob-taining novel compounds with potential anticoagulant activity.Fig. 2. 13C-NMR spectra of 5referencesF. Borges, F. Roleira, N. Milhazes, L. Santana and E. Uriarte. Simple Coumarins andAnalogues in Medicinal Chemistry: Occurrence, Synthesis and Biological Activity. Cur-rent Medicinal Chemistry, 2005, 12, 887-916.Ufer, M. Comparative pharmacokinetics of vitamin K antagonists warfarin, pherpro-coumon and acenocoumarol Clin. Pharmacokinet. 2005 44(12), 1227-1246M. Beinema; J. R. B. J. Brouwers; T. Schalekamp; B. Wilffert. Pharmacogenetic differ-ences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost2008; 100, 1052-1057.D. Tassies, C. Freire, J. Pijoan, S. Maragall, J. Monteagudo, A. Ordinas, J. C. Reverter. Phar-macogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms influencedose requirements and stability of anticoagulation. Haematologica 2002, 87, 1185-1191.NEOChEKUVAN PRODUKT PRI REAKTsIJANA ATsENOKUMAROl I FOSFORIlkhlORIDE. Stanoevska1, K. Mladenovska1,A. Potseva Panovska1, B. Mikkhova2, E. Popovski31 Farmatsevstki fakultet, Univerzitet Sv. Kirli i Metodij,Vodnjanska 17, Skopje, Makedonija2 Institutu za organska khemija so tsentar za fitokhemija, BugarskaAkademija na Naukite, Ul. Akademik G.Bonchev, Sofija, Bugarija3Institut za khemija, Prirodno-matematichki gakultet, UniverzitetSv. Kirli i Metodij, Arkhimedova 5, Skopje, MakedonijaVOVEDKumarinite se golema klasa soedinenija koi vo svojata strukura gosodrzhat prstenot na benzo-a-piron (2N-1-benzopiran-2-on). Fami-lijata na kumarinite se karakterizira so shiroka strukturna razli-chnost i vo zavisnost od supstituentite na benzenoviot i piron-skiot prsten, kumarini-te se klasifitsirani vo slednite katego-rii: (a) ednostavni kumarini, (b) furano kumarini, (v) piranokumarini (g) bis i triskumarini i (d) kumarinoligani. Ednostavnitekumarini i nivnite analozi, kako bis i tris kumarinite postojanogo privlekuvaat nauchniot interes pred se zaradi nivnita shirokabioloshka aktivnosta i toa kako antikoagulansi, antiin-flamatorni, antitumorni, antimikrobni i antioksidantni agensi.Dokazhano e deka ovie soedinenija se aktivni i na nivo natsentralniot nerven sistem, a poseduvaat i svojstva na enzimskiinkhibitori. Zaradi navedenite osobini kumarinite se osobenointeresni od aspekt na nivno re-dizajniranje, sinteza iponatamoshen razvoj [1].Atsenokumarolot (1) [(RS)-4-khidroksi-3-[1-(4-nitrofenil)-3-oksobu-til]-2H-khromen-2-on, logP 1,98; logS (predvidena) -4,53] e antiko-agulans koj deluva kako antagonist na vitaminot K. Molekulot naatsenokumarolot ima eden khiralen tsentar koj ukazhuva na postoenjena dve enantiomerni formi. (R)-(+)-atsenokumarolot ima podolgopoluvreme na plazma eliminatsija i pobaven plazmatski klirenssporedeno so (S)-(-)-enantiomerot. (R)-(+)-enantiomerot e popoten-ten in vivo kako antigoagulans od (S)-(-)-enantiomerot, i voglavno eodgovoren za sevkupniot antigoagulanten odgovor [2].Atsenokumarolot se metabolizira voglavno so CYP2C9, dodekanegova tsel na enzimot vitamin K epoksidaza e VKORC1. Genetskitevarijatsii vo CYP2C9 i VKORC1 se asotsirani so varijabilnosta vopotrebnata doza na atsenokumarolot, prekumerna antikoagulatsija,opasnost od krvarenje i stabiliatsija [3,4].Trgnuvajki od atsenokumarolot kako vodechko soedinenie, tselta naovoj trud beshe da se sintetizira nov 4-aminoderivat na atsenokuma-rolot. Zaradi elektronskata slichnost na kislorodniot atom (khi-droksilna grupa) i azotniot atom (amino grupa) pretpostavivmedeka (RS)-4-amino-3-[1-(4-nitrofenil)-3-oksobutil]-2H-khromen-2-on(3) mozhe da bide potentsijalen bioizoster na atsenokumarolot.MATERIJAlI I METODISinteza na(rs)-2-metil-4-(4-nitrofenil)pirano(-) [3,2-c]khromen-5-on (4)Smesata od (RS)-Atsenokumarol (Alkaloida Chemical Co.) i fosforilkhlorid (POCl3) (Merck Chemicals) beshe zagrevana na 70oC vo periodod 4 chasa. Ponatamu, reaktsionata smesa beshe oladena do sobnatemperatura a potoa beshe isturena vo sitno zdroben mraz i po-stojano meshana za vreme od 45 min. Pritoa bea formirani krista-li od 4 koi bea filtrirani i premieni so ladna voda. Dobienotosoedinenie beshe karakterizirano so FTIR, 1H-NMR (Sl. 1) i 13C-NMR (Sl. 2).Sl. 1. 1H-NMR spektar na 4344PETTI KONGRES NA FARMATsIJATA SO MEGjUNARODNO UChESTVOMakedonski farmatsevtski bilten 57 (dodatok), 2011FARMATsEVTSKA KhEMIJA / BIOMOLEKULARNI NAUKIposter prezentatsiiREzUlTATI I DISKUSIJAReaktsijata na 1 so fosforil khlorid beshe izvedena za da se dobie4-khloro derivatot na atsenokumarolot 2a. Ponatamu dobivanjeto natselnoto soedinenie 3 beshe planirano e preku reaktsija na amoni-jak so intermedierot 2a (Shema 1). Megjutoa, vo prviot chekor, pokrajsupstitutsijata na khidroksilnata grupa na polozhba 4 vo kumarin-skiot del, se odviva i neplanirana tsiklizatsija. Vo intramolekul-arna nukleofilna reaktsija, kislorodniot atom od khidroksilnatagrupa na enolatnata forma 2b go zamenuva khlorniot atom pri shtobeshe dobieno soedinenieto 4. Iako reaktsijata beshe izvedena natri razlichni temperaturi (70 oC, 90 oC i Tv na fosforil khloridot),vo site obidi kako produkt na reaktsijata beshe izolirano soedine-nieto 4. Ottuka, ponatamoshnite istrazhuvanja kje se nasochat konsinteza i izolatsija na soedinenieto 2a kako intermedier zadobivanje na novi soedinenija so potentsijalna antikoagulativnaaktivnost.Sl. 2. 13C-NMR spektar na 4REFERENTsIF. Borges, F. Roleira, N. Milhazes, L. Santana and E. Uriarte. Simple Coumarins andAnalogues in Medicinal Chemistry: Occurrence, Synthesis and Biological Activity. Cur-rent Medicinal Chemistry, 2005, 12, 887-916.Ufer, M. Comparative pharmacokinetics of vitamin K antagonists warfarin, pherpro-coumon and acenocoumarol Clin. Pharmacokinet. 44(12), 1227-1246M. Beinema; J. R. B. J. Brouwers; T. Schalekamp; B. Wilffert. Pharmacogenetic differ-ences between warfarin, acenocoumarol and phenprocoumon. Thromb Haemost2008; 100, 1052-1057.D. Tassies, C. Freire, J. Pijoan, S. Maragall, J. Monteagudo, A. Ordinas, J. C. Reverter.Pharmacogenetics of acenocoumarol: cytochrome P450 CYP2C9 polymorphisms in-fluence dose requirements and stability of anticoagulation.